SCHEMBL3221597

SCHEMBL3221597

Nc1ccc2nn(-c3ccc([N+](=O)[O-])cc3)nc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.65
KMT2A Q03164 11/20 0.65
MAPT P10636 9/20 0.60
NPC1 O15118 8/20 0.60
ALDH1A1 P00352 8/20 0.60
RAB9A P51151 7/20 0.60
KDM4E B2RXH2 4/20 0.60
ATM Q13315 2/20 0.60
TP53 P04637 2/20 0.60
HPGD P15428 2/20 0.60
CASP1 P29466 2/20 0.60
CASP7 P55210 2/20 0.60
HSD17B10 Q99714 2/20 0.60
GAA P10253 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
STAT1 P42224 1/20 0.59
POLB P06746 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
PKM P14618 1/20 0.52
PPARG P37231 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038573 0.87 MEN1 (0.56) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL3039249 0.82 NPC1 (0.53) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL3028821 0.82 PPARG (0.46) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL7047234 0.82 MEN1 (0.79) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL13298656 0.80 KDM4E (0.55) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL27627290 0.79 PPARG (0.63) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL14281089 0.79 MEN1 (0.51) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL27647508 0.79 MAPT (0.56) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL3040216 0.78 NPC1 (0.53) MEN1KMT2AMAPTNPC1ALDH1A1
SCHEMBL3216453 0.78 RAB9A (0.58) MEN1KMT2AMAPTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0925612-B1 GALLIUM DOPED LITHIUM MANGANESE OXIDE SPINELS (LiGaxMn2-xO4) AS ACTIVE CATHODE MATERIAL FOR LITHIUM OR LITHIUM-ION RECHARGEABLE BATTERIES WITH IMPROVED CYCLING PERFORMANCE CONSIGLIO NAZIONALE RICERCHE (IT) 2000-09-13 EP claimed
JP-55125535-A None JP disclosed
US-9182553-B2 Optical switch activator with glowable member COX, CHRISTOPHER E. 2015-11-10 US disclosed
US-20140153869-A1 Optical Switch Activator with Glowable Member COX, CHRISTOPHER E. 2014-06-05 US disclosed
US-8658962-B2 Optical switch with glowable activator portion COX, CHRISTOPHER E. 2014-02-25 US disclosed
US-20130121637-A1 Optical Switch Activator with Glowable Member COX, CHRISTOPHER E. 2013-05-16 US disclosed
US-8334501-B1 Optical switch activator with glowable member COX, CHRISTOPHER E. 2012-12-18 US disclosed
US-7902989-B2 Optical switch COX, CHRISTOPHER E. 2011-03-08 US disclosed
WO-2010093929-A1 AN OPTICAL PRESSURE ACTIVATED DEVICE COX RALEIGH L (US) 2010-08-19 WO disclosed
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US disclosed
US-20100066548-A1 Optical Switch COX, CHRISTOPHER E. 2010-03-18 US disclosed
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED (BS) 2010-02-25 US disclosed
EP-1986643-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2008-11-05 EP disclosed
WO-2007091107-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2007-08-16 WO disclosed
EP-0329573-B1 DEVICE FOR AFFIXING A SINGLE OR MULTIPLE DOME, PARTICULARLY A SKYLIGHT OR VENTILATING SKYLIGHT ECODIS (S.A.R.L.) (FR) 1991-10-09 EP disclosed
EP-0329573-A1 Device for affixing a single or multiple dome, particularly a skylight or ventilating skylight ECODIS (S.A.R.L.) (FR) 1989-08-23 EP disclosed
EP-0235660-A1 Isocyanato-benzotriazoles and process for their preparation BAYER AG (DE) 1987-09-09 EP disclosed
JP-S55125535-A TRANSFER MAGNETIC SHEET HITACHI MAXELL LTD 1980-09-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SMN1; SMN2, CPT1B, GYS1 MEN1 2802/4885KMT2A 3534/4885MAPT 4772/4885
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy CPT1B, PYGM, MTPN MEN1 3587/4885KMT2A 3863/4885MAPT 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.